Dr. Jorge Estrella Leyva

Dr. Jorge L. Estrella M.D.

President & Chief Medical Officer

Dr. Estrella is the founding President & Chief Medical Officer of ESTERN Medical, Clinical Research Organization (CRO) Group Globally.

Dr. Estrella is responsible for evaluating Biotech's, Pharmaceutical and Medical Device Companies with novel technologies as well as potential business alliances and partnership strategic collaborations to determine the company operational strategic priorities and influence the company R&D organizational strategy senior management across all of its business units in the clinical research organization.

Dr. Estrella brings more than 15 years of experience in the clinical research development programs in diverse global corporate pharmaceutical and medical device companies, with an extensive experience in the areas of Cardiovascular, CNS, Infectious Diseases and Diagnostic Imaging clinical research development field as well as a unique combination of entrepreneurial, scientific business expertise and bringing those novel R&D products to present and future global market clinical indications approvals.

Prior to founding the ESTERN Medical CRO Group. Dr. Estrella has held diverse positions in the clinical development research field, at EPIX Pharmaceuticals Inc., as the Director Clinical Development, in Cambridge-Boston, Massachusetts, during the business and R&D collaboration-partnership with Schering Pharmaceuticals AG & Berlex Laboratories LLC. (Now known as BSP - Bayer Schering Pharma AG).

During his work life at EPIX he was in charged of two of the most important company novel drug development clinical compounds INDs & NDAs agents at EPIX Pharmaceuticals brand name Vasovist® (gadofosveset Trisodium) or also know as ABLAVAR®. The First Imaging Agent Approved For Magnetic Resonance Angiography (MRA / MRI) in the U.S. an injectable intravascular contrast agent designed to provide improved imaging of the cardiovascular and peripheral artery system through magnetic resonance angiography imaging (MRA / MRI) approved for global marketing in the United States , Europe and in 40 countries and EP-2104R a diagnostic radiological imaging novel pharmaceutical agent under present development, designed for enabling detection of blood clots using Magnetic Resonance Imaging.

Prior to joining EPIX Pharmaceuticals, he worked in the Medical Device industry as as the Senior Physician Director-Clinical Trials Coordinator at Guidant Corporation Inc., (ACS) Advanced Cardiovascular Systems in Santa Clara California Peripheral & Stent Division, (now known as Boston Scientific Inc). Having culminating with Guidant, with the HERCULINK® Stent platforms.

Dr. Estrella also acquired a bast experience in CNS an extensive knowledge working in collaboration in the global clinical CNS development of RISPERDAL® (Risperidone) and Antipsychotic drugs used to treat symptoms of psychiatric disorders such as schizophrenia and bipolar disorder, where he held a positions in the medical clinical research department at Janssen Pharmaceuticals Inc.

Dr. Estrella is internationally well recognized for his broad expertise in global clinical research trail development in the pharmaceutical and medical device scientific community in some of the most prestigious medical, academic institutions as well as biotech, pharmaceutical and medical device companies.

Dr. Estrella received his medical degree from the Autonomous University of Guadalajara in Mexico (UAG). He completed his residency training at the National Institute of Nutrition in Mexico City in the Department of Internal Medicine, where he completed his clinical and research medical training.